A Decade of C3 Glomerulopathy-A Nationwide Cohort Study.

Rick H Overwijk, Fiona R Kolbinger, Mark Eijgelsheim, Olaf M Dekkers, Andreas Kronbichler, Ingeborg M Bajema

Abstract read

In one paragraph

Article in Kidney international reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Rick H OverwijkDivision of Pathology, Department of Pathology and Medical Biology, University Medical Center Groningen and University of Groningen, Groningen, The Netherlands.

Fiona R KolbingerWeldon School of Biomedical Engineering, Purdue University, West Lafayette, Indiana, USA.

Mark EijgelsheimDivision of Nephrology, Department of Internal Medicine, University Medical Center Groningen and University of Groningen, Groningen, The Netherlands.

Olaf M DekkersDepartment of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.

Andreas KronbichlerDepartment of Internal Medicine IV, Nephrology and Hypertension, Medical University Innsbruck, Innsbruck, Austria.

Ingeborg M BajemaDivision of Pathology, Department of Pathology and Medical Biology, University Medical Center Groningen and University of Groningen, Groningen, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: C3 glomerulopathy (C3G) is a rare but devastating disease affecting children and adults. It frequently leads to end-stage kidney failure, and currently no specific treatment exists. C3G is used as a collective term for dense deposit disease (DDD) and C3 glomerulonephritis (C3GN) and is thought to sometimes occur in postinfectious settings (C3-PIGN). Currently, little is known about the incidence and distribution of subtypes in the population. We analyzed a large cohort of patients with C3G in the Netherlands regarding incidence and disease subtype distribution in relation to geographical factors and histopathological findings. Methods: A search in the Dutch Nationwide Pathology Databank (Palga) was performed to identify patients diagnosed with C3G from January 2014 until December 2023, subsequently ascertained by 2 independent observers. We assessed the correlation of disease subtypes with glomerular patterns, and the geographical distribution was charted. Results: The selection resulted in a cohort of 280 patients consisting of C3GN ( Conclusion: Our results show consistent assessment of kidney biopsies across the country and absence of geographical factors influencing disease development.

Indexed as

C3 glomerulonephritisC3 glomerulopathycomplement factordense deposit diseasepostinfectious glomerulonephritis

Identifiers

PMID41537099

DOI10.1016/j.ekir.2025.11.007

PMCPMC12795654

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.